Back

Prevalence of REDUCE-IT trial eligible patients in a coronary disease follow-up program

19 May 2025 (11:17 - 12:25)
Organised by: Logo
Congress Presentation Part of: ePosters in risk factors and prevention Obesity HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Marta Leite

Hospital Center Vila Nova Gaia, Porto (Portugal)

6 More presentations in this session

Presentation thumbnail
Heart failure in conventional cardiac pacing: influence of obesity and T2DM
Assistant Professor L. Cirin (Timisoara, RO)
Abstract Slides Video
Presentation thumbnail
The influence of diabetes on cardiac rehabilitation outcomes: a comparative analysis
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) levels in acute coronary syndrome: analysis of sex, age, and cardiovascular risk factors
Doctor M. Leite (Porto, PT)
Abstract Slides Video
Presentation thumbnail
The influence of guideline updates for target LDL values in patients with acute coronary syndrome
Doctor M. Leite (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Follow-up after acute coronary syndrome: advancing cardiovascular risk management
Doctor M. Leite (Porto, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in risk factors and prevention

The Event

Event poster

Heart Failure 2025

19 May 2025 11:17 CET
You may be interested in
thumbnail
Congress Presentation
Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT
thumbnail
Congress Presentation
Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT
thumbnail
Congress Presentation
Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources